Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Human Cerebral Organoids Test for CJD Treatment

Stem Cells & Brain Disorders Project Recruitment at NIMHANS

An E-textile that controls biological energy when worn

Human Cerebral Organoids Test for CJD Treatment
  • BiotechToday
  • World

Human Cerebral Organoids Test for CJD Treatment

bioxone March 16, 2021March 16, 2021

Thota Kanishka Rao, Amity University Kolkata

In almost two years, after evolving a human cerebral organoids system to work Creutzfeldt-Jakob disease (CJD), researchers have further studied a model to screen drugs for budding CJD treatment. 

Human Cerebral Organoids are small bundles of human synapses generated using human skin cells. They range from the size of a poppy seed to a pea. CJD is a lethal neurodegenerative brain disease in humans brought about by infectious prion proteins, affecting around 1 in every 1 million individuals every year. It can emerge suddenly, resulting from an innate mutation inside the prion gene, or emerge because of disease, for instance, from eating defiled meat items.

There are no preventive or therapeutic medicines for CJD. A prominent illustration of this was exhibited in the United Kingdom during the 1990s following an outbreak of bovine spongiform encephalopathy in cattle.

The absence of a human CJD model has been a significant hindrance ruining the disclosure of likely treatments. Studies in mice have not been able to distinguish treatments that were then viable when attempted in patients. The human cerebral organoids CJD model holds a guarantee that this limitation can be wiped out. Cerebral organoids have organisation, structure, and electrical signalling structure like human brain tissue.

Since they can survive in a controlled climate for quite a long time, cerebral organoids likewise are ideal for considering nervous system infections throughout protracted timeframes. Cerebral organoids have been utilized as models to study Zika virus infection, Alzheimer’s disease, and Down syndrome.

During this CJD study, the researchers tried pentosan polysulfate (PPS) to decide its possible preventive and helpful advantages. In the study, PPS treatment decreased the infection pointers by 10-fold or more without causing tissue mortalityPPS is a benchmark anti-prion compound in research centre experiments, yet it is once in a while utilised clinically because it requires direct organisation into the cerebrum.

While it might expand a patient’s life, PPS has not been appeared to improve quality of life. Be that as it may, utilising the anti-prion properties of PPS with the new human organoid CJD model permitted the researchers to evaluate the estimation of this model framework for drug disclosure.

Also read: GATA6+ macrophages: not just phagocytes but also wound healers!!!

Source:B Groveman and NC Ferreira et al. Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob Disease. Scientific Reports DOI: http://10.1038/s41598-021-84689-6 (2021).

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged C Brain cerebrum CJD Creutzfeldt-Jakob disease human cerebral organoid organoid

One thought on “Human Cerebral Organoids Test for CJD Treatment”

  1. Pingback: An E-textile that controls biological energy when worn - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

An E-textile that controls biological energy when worn

bioxone March 16, 2021

Sristi Raj Rai, Amity University Kolkata  Energy is a transferable property of a body that can neither be created nor destroyed. It is the energy that is required to carry out any kind of work and has various forms (potential, kinetic, thermal, electrical, chemical, biological, etc). Keeping the transferable property in mind, nano engineers from […]

biological energy

Related Post

  • BiotechToday
  • World

The curious case of Covid-19 Re-infection

bioxone June 22, 2021June 21, 2021

Madhavi Bhatia, NIPER Guwahati Coronavirus infection recovery provides a significant amount of immunity to individuals but there are some cases that have revealed that even after successfully recovering from COVID-19 infection there are chances of re-infection. This is mainly found to be due to mutation in the virus leading to different variants like alpha and […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

MYCN protein expression level in neuroblastoma patients predicts prognosis better

BioTech Today February 3, 2023February 3, 2023

Charvy Rana, Department of Pathology, AIIMS, New Delhi What is MYCN protein? Cancer often involves the inactivation of tumor-suppressor genes and/or over-activation of oncogenes. The MYCN proto-oncogene is one such example, implicated for its amplified or “oncogenic” status in several neuronal and non-neuronal cancers (those of lung, ovaries, prostate, and more)1. Normally expressed during the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Effect of the double mutant variant of COVID 19

bioxone March 31, 2021March 31, 2021

Sampriti Roy, University of Calcutta Coronavirus yet again presents new issues to worry about this year, aside from the devastating global pandemic it has caused. Over the last few weeks, a new “double mutant variant” has been detected in some pockets of India, particularly Delhi and Maharashtra. This “double mutant” strain has been found in […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy